For biopharma innovation to succeed and accelerate, companies must stop duplicating their efforts and share valuable information.
While advanced therapy medicinal products (ATMPs) hold great promise, the path to exploiting the technology has been challenging. Christian K. Schneider outlines the five strategies that must be considered to increase the success rates of development programs, while avoiding some of the common pitfalls.